Medicon Valley Biomedical Newsletter

2cureX is a novel drug discovery company that integrates chemical diversity and biological complexity to rapidly generate advanced drug candidates for the treatment of cancer. 2cureX presents a...

ALK-Abelló A/S has launched its tablet-based vaccine against grass pollen allergy, GRAZAX, in Germany. GRAZAX is the first allergy tablet to address the underlying cause of grass pollen allergy and no...

Astion Pharma A/S has started recruiting patients suffering from seborrheic dermatitis in a Phase IIb study with ASF-1057. ASF-1057 is a potent anti-inflammatory product candidate, for which human pro...

BioGaia AB has signed an agreement with HSO Pharma, Austria, giving the company exclusive rights to market BioGaia's probiotic tablets and drops in Germany. BioGaia and HSO entered into a d...

BioGaia AB has signed an agreement with PT Kalbe Farma Tbk in Indonesia. The agreement gives Kalbe Farma exclusive rights to distribute BioGaia´s probiotic tablets and oral health products in Indonesi...

Copenhagen University is to house three new centres for basic research which will be funded by Denmark's Basic Research Fund. The fund includes Euro 46 million which will be used to finance eight ...

Curalogic A/S is expanding its clinical Phase III trial, RPE 04, involving the product for ragweed allergy treatment to also include patients from Europe. The reason behind this is to raise the produc...

The Gambro Group AB will develop into three independent companies. Gambro Renal Products will become the new Gambro. Gambro Healthcare and Gambro BCT will gradually become independent companies with f...

LEO Pharma A/S and Galapagos NV have announced a collaboration focusing on the discovery of new antibacterial agents. BioFocus DPI, Galapagos' service division, will use a subset of its natural co...

Lifecycle Pharma A/S has been listed on the Copenhagen Stock Exchange. Lifecycle Pharma is classified as a mid-cap company included in the exchange's healthcare section. It becomes the fifth compa...

Ludesi AB has announced that Johns Hopkins Bayview Proteomics Center, JHBPC, in Baltimore has selected Ludesi for its complete image analysis processing of two-dimensional, 2D, gels. The JHBPC has sel...

The inflammatory research group at the Medical faculty at Lund University headed by Professor Rikard Holmdahl has been appointed one of the best centres for rheumatic research in Europe. It is ...

Researchers at Lund University and the Karolinska Institute have received a grant of EUR 2.19 million which will enable them to develop a new treatment method for Parkinson's patients to replace l...

Researchers into diabetes at Lund University have received a grant of EUR 2.5 million from the Knut and Alice Wallenbergs foundation. The grant is to be invested in a new technology in order to help t...

A research project initiated by a Scandinavian consortium including Visiopharm A/S and Dako A/S, which will advance the analysis of cancer tissue, has been awarded EUR 3 million by the European Union....

NeuroSearch A/S has dosed the first patient in a Phase I clinical study with ACR325, adopaminergic stabiliser for the treatment of psychosis including bipolar disorder.Current treatment options for bi...

NeuroSearch A/S has obtained regulatory approval to perform a human metabolic Phase I/II study with tesofensine. The study will be a two-armed, placebo-controlled, parallel group study, which will inc...

TopoTarget A/S and CuraGen Corp. have announced the initiation of patient dosing in a Phase II clinical trial evaluating the antitumour activity of intravenous PXD101, a small molecule histone deacety...

TopoTarget A/S and CuraGen Corporation have announced the initiation of patient dosing in a Phase II open-label, multi-centre clinical trial evaluating the efficacy and safety of intravenous PXD101, a...